However, there is some degree of unpredictability in the lung cancer market, at which the company hinted during its earnings call. The competition is increasing, as lung cancer is a key target for big pharma players because of the strong market potential. Roche launched Tecentriq last year for bladder cancer, but its data around lung cancer seems promising and soon it may compete directly with Opdivo. In fact, Opdivo lost some share in the lung cancer market in the first quarter. Diversification Is EssentialNeedless to say, Bristol-Myers Squibb would benefit from diversifying its revenue sources, which would make it less susceptible to competitive and clinical trial data shocks.

Source: Forbes May 03, 2017 15:45 UTC